Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: J Allergy Clin Immunol. 2017 Dec 21;142(4):1066–1079.e6. doi: 10.1016/j.jaci.2017.10.044

Figure 2. Eosinophilic airway inflammation and mucous cell metaplasia are increased in HDM-challenged Lrp1fl/fl; CD11c-Cre mice.

Figure 2

A) Lrp1fl/fl and Lrp1fl/fl; CD11c-Cre mice were sensitized with two intraperitoneal injections of 100 μg HDM (with alum 40 mg ml−1) on day 0 and day 4 and challenged on days 8, 10, 12 and 15 by intranasal administration of HDM (50 μg) before harvest and endpoint analysis on day 17. B) The number of total BALF inflammatory cells and inflammatory cell types (eosinophils (Eos), alveolar macrophages (AM), neutrophils (PMN) and lymphocytes (Lymph)) from saline- and HDM-challenged Lrp1fl/fl; CD11c-Cre and Lrp1fl/fl mice (n = 7 – 16 mice per group, * P< 0.01, HDM-challenged Lrp1fl/fl; CD11c-Cre versus Lrp1fl/fl, one-way ANOVA with Sidak’s multiple comparison test). C) Representative lung histology sections stained with hematoxylin and eosin (H&E) or Periodic acid-schiff (PAS). Scale bars 100 μm for the 200× images and 20 μm for the 1,000× images. D) Quantification of mucous cell metaplasia as assessed by the percentage of airways that contained PAS+ cells. Data are mean ± SEM (n = 5 – 7 mice per group, * P < 0.05, HDM- challenged Lrp1fl/fl; CD11c-Cre versus Lrp1fl/fl mice, Mann-Whitney test). Results shown are pooled data from two independent experiments.